Translate
Healthcare Case Studies
Discover how leading biopharmaceutical, medical technology, and healthcare investment firms leverage CURA to streamline regulatory affairs, mitigate compliance gate risks, and accelerate market approvals.
Select an industry domain below to explore active performance trackings and historical outcomes.
76%
Historical compliance delta across matching programs.
1.8 Mos
Median cycle time recorded from technical file kick-off.
99.9%
Dossiers approved without undergoing correction holds.
8.7x
Average administrative and legal expense ratio savings.
Novara Oncology Prime
The Challenge
Reviewing unstructured FDA advisory verdicts and historic oncology pipelines draft guidelines manually kept regulatory affairs analysts occupied for dozens of hours weekly, slowing IND submission pacing.
The Solution
Deployed CURA's CURA Intellect core monitoring FDA oncologist advisory boards, European registries, and target clinical trial endpoints in real-time.
The Outcome
Unlocked a competitive clinical trial whitespace. Shortened pre-submission pathway planning loops from 6 months down to 2.4 months, saving $420k in unnecessary compliance overhead.
Pre-Submission Regulatory Dossier Preparation Timeline (Weeks)
Comparative metrics verifying standard performance against automated CURA acceleration.
- CURA Accelerated Pathway
- Traditional Industry Standard
"CURA provided the clinical-to-regulatory clarity we needed. We launched our Phase II protocol EGFR trials with comprehensive guidance, beating our competitor to market by 3 months."
Aegis Spinal Systems
The Challenge
An orthopedic implant manufacturer was facing urgent EU MDR transitional recertification requirements amidst unprecedented Notified Body approval backlogs and strict MDCG structural validation guidelines.
The Solution
Deployed the CURA Biomedical Device Intelligence Suite to dynamically audit technical documentation folders against ISO 14155 and MDCG 2022-21 compliance checklists.
The Outcome
Coordinated technical file preparation and localized Notified Body submission queues. Cleared the CE Mark authorization 4 months ahead of the sunset timeline, avoiding EU market freeze.
Technical Dossier Quality Score & Audit Progress (%)
Comparative metrics verifying standard performance against automated CURA acceleration.
- CURA Accelerated Pathway
- Traditional Industry Standard
"Without CURA's immediate MDR extension tracking, our European operations would have ground to a halt. It is our ultimate safety shield."
Zenith Therapeutics
The Challenge
Preparing harmonized global drug approval dossiers across FDA (US), EMA (EU), and PMDA (Japan) concurrently triggered repetitive validation rejections due to regional discrepancies in reporting safety alerts.
The Solution
Utilized CURA's Country-Specific Intelligence Module to automate cross-jurisdiction delta mappings and localized compliance checks.
The Outcome
Reduced structural rejection occurrences from 24% down to under 1.5%. Achieved a multi-region synchronized launch schedule with zero regulatory pauses or warnings.
Structural Regulatory Rejection & Warning Incidents
Comparative metrics verifying standard performance against automated CURA acceleration.
- CURA Accelerated Pathway
- Traditional Industry Standard
"The cross-jurisdictional dossier auto-verification saved us months of redundant dossier translation work and eliminated hundreds of compliance errors."
